We invest to cure disease
Join our portfolio of founders seeking new cures
Smarter investments, greater impact
At Vibe Bio, we believe that groundbreaking cures shouldn’t be sidelined due to funding gaps or analytical limitations. Our venture fund is dedicated to empowering visionary founders developing platform technologies and therapeutics, especially those targeting rare or overlooked diseases.
Just as we empower our biopharma partners to make smarter BD and in-licensing decisions, we also apply VibeOne’s AI capabilities to guide, validate, and accelerate the success of our own investment portfolio.
Looking to raise? Let’s connect.
Seeking ambitious founders
We invest in exceptional founders developing high-potential therapies – regardless of modality o disease area. If you’re building something bold, let’s talk.
Gain an edge with AI
Our AI platform goes beyond due diligence. We share insights with our portfolio teams – from risk analysis to competitive benchmarking – to help them plan, be smarter, and move faster.
AI-enhanced
Utilizing our proprietary AI platform, VibeOne, we conduct rigorous due diligence to assess risk, benchmark against competitors, and plan strategically.
“The spirit of collaboration began before the investment.
Even during diligence, a mantra of ‘What can we do to help?’ has been evident from the Vibe Bio team.”
Evan Sussman, CEO and Co-founder, GranataBio
Our portfolio
Explore our portfolio of breakthrough biotech companies, vetted and backed by Vibe Bio.
Eigen Therapeutics
Eigen has created an innovative platform to develop a co-therapy approach for the treatment of children with hematological malignancies.
Eigen’s approach is to expand the therapeutic window through a unique drug combination that includes a priming therapy to improve the safety and efficacy of existing antigen-directed therapies that can be used to treat a broader cohort of patients. Patients would first be treated with a priming agent to transiently and uniformly upregulate target antigens specifically on cancer cells and not on normal cells – creating an ideal target expression profile that will enable antigen-directed therapy to more effectively eliminate tumor cells while minimizing toxicity. Learn more about Eigen’s groundbreaking work.
Granata Bio
Granata Bio is a biopharma company focused on women’s health and infertility. While incidence of infertility in the US mirrors that of other developed countries, the cost of US fertility treatment is often borne by the patient, and this presents a significant barrier to treatment.
Founded in 2018, Granata Bio’s model is to identify and in-license strategic medications used in IVF outside of the US for clinical development and commercialization in North America. By doing so, we hope to expand therapeutic options for patients, decrease cost, and increase access to care for every patient seeking fertility treatment on their path to parenthood. Explore the Granata Bio website to learn more about their progress.
Somite AI
Somite.ai is developing AI foundation models for human stem cells to drive novel cell therapies at scale. Their full-stack approach generates data at 1,000x lower cost and trains large-scale models with unmatched predictive power models to discover, refine, and optimize high-impact applications in cell therapy.
The founding team includes repeat AI entrepreneur Dr. Micha Breakstone (Chorus.ai, acquired for $575M), the Head of the Fundamental AI Group at MIT (pioneered foundational scaling laws research), and four Harvard Medical School professors (including the Chair of the Genetics Department) and National Academy of Sciences/Medicine members. Launched in 2024, Somite is Boston-based, and has raised over $11M in pre-seed funding. Visit Somite AI’s website to discover more.
Supporting founders beyond capital
Our commitment extends beyond funding. We partner closely with our portfolio companies, offering:
Network Access: Connecting founders with a community of scientists, investors, and industry experts.
Strategic Insights: Leveraging AI-driven analyses to inform development pathways and identify opportunities.
Operational Support: Assisting with planning, regulatory strategies, and market positioning.
Funding with purpose: Your questions answered
How can potential partners collaborate with Vibe Bio?
Our due diligence team considers an array of variables in order to make a decision based on scientific merit and clinical opportunity. Our mission to find every cure for every community empowers us to invest in a variety of therapeutic areas.
Can I invest in the companies that Vibe Bio helps to finance? If so, how?
Yes, you can! Get in touch to learn more about investing opportunities.
How can I get funding for my biotech company?
If you are a founder-led, early-stage biotech looking to create an impact to find cure, reach out to us so we can learn about your promising project, upcoming milestones, and your path to the next crucial stage for your organization.
How does Vibe Bio diligence projects?
Our team performs thorough analysis of the scientific and business data in order to choose the best options for our portfolio. To help us make better, more accurate, and faster decisions, we use VibeOne for AI-driven assessment of drug program potential.
Join our mission
Vibe Bio uses AI-driven insights to inform investment decisions, improve real-world outcomes, and benchmark against industry standards. Learn how you can join us.